Value of Laboratory Biomarkers in Prediction of Outcome in Septic Patients - Trial NCT06338124
Access comprehensive clinical trial information for NCT06338124 through Pure Global AI's free database. This phase not specified trial is sponsored by Egymedicalpedia and is currently Not yet recruiting. The study focuses on Sepsis. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Egymedicalpedia
Timeline & Enrollment
N/A
Apr 01, 2024
Apr 01, 2025
Primary Outcome
Mortality
Summary
Sepsis is defined as a dysregulated host response to infection . Despite ongoing efforts,
 both the incidence and mortality of sepsis have demonstrated limited reductions over the past
 years,There are several biomarkers that have already been studied for the early diagnosis of
 sepsis. Some of these markers can be used in risk prediction and monitoring the outcome of
 sepsis .
 
 Some of these markers as procalcitonin and CD14, are costly and not feasible options for low-
 and middle-income countries . While other biomarkers are feasible and accessible to be
 evaluated as Triglyceride\glucose index (TyG) , Relative Distributive Width of red blood
 corpuscles to albumin ratio (RAR), C-reactive protein,Neutrophile \Lympocyte ratio and serum
 lactate levels .
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06338124
Non-Device Trial